Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Shares Outstanding (Diluted Average) (2019 - 2025)

Standard Biotools (LAB) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $382.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 2.99% to $382.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $382.6 million, a 2.99% increase, with the full-year FY2024 number at $353.2 million, up 346.24% from a year prior.
  • Shares Outstanding (Diluted Average) was $382.6 million for Q3 2025 at Standard Biotools, up from $379.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $382.6 million in Q3 2025 to a low of $74.7 million in Q1 2021.
  • A 5-year average of $180.1 million and a median of $79.0 million in 2023 define the central range for Shares Outstanding (Diluted Average).
  • Peak YoY movement for Shares Outstanding (Diluted Average): increased 1.09% in 2023, then skyrocketed 370.5% in 2024.
  • Standard Biotools' Shares Outstanding (Diluted Average) stood at $75.8 million in 2021, then grew by 3.32% to $78.3 million in 2022, then rose by 1.09% to $79.2 million in 2023, then skyrocketed by 346.24% to $353.2 million in 2024, then increased by 8.32% to $382.6 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Shares Outstanding (Diluted Average) are $382.6 million (Q3 2025), $379.4 million (Q2 2025), and $378.2 million (Q1 2025).